A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/0912/31/11

Funding

  • Quintiles Inc: $118,031.00